An enzymatic advance in nicotine cessation therapy - PubMed (original) (raw)

An enzymatic advance in nicotine cessation therapy

Song Xue et al. Chem Commun (Camb). 2018.

Abstract

A nicotine-degrading enzyme termed NicA2 was altered (NicA2-J1) through fusion of an albumin binding domain to increase its half-life. Examination of NicA2-J1 in vivo demonstrated a complete blockade of brain nicotine access, which in turn blunted nicotine's psychoactive effects. These data further support development of pharmacokinetic nicotine cessation therapeutics.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

There are no conflicts to declare.

Figures

Fig.1

Fig.1

Pharmacokinetics of NicA2 and NicA2-J1 in rat serum.

Fig. 2

Fig. 2

Effect of NicA2-J1 during nicotine withdrawal in rats. NicA2-J1 blocks total withdrawal score (A), hyperalgesia (B) and irritability like behaviour (C) during withdrawal. (Sal: saline; Nico: nicotine)

Fig. 3

Fig. 3

Nicotine concentrations in rat blood (A) after 1 or 5 days and brains (B) after 7 days of NicA2-J1 administration. (ND: not detected)

References

    1. World Health Organization., WHO Report on the Global Epidemic, 2013: Enforcing Bans on Tobacco Advertising, Promotion, Sponsorship, WHO Press, Geneva,Switzerland, 2013.
    1. Biener L, Reimer RL, Wakefield M, Szczypka G, Rigotti NA and Connolly G, Am. J. Prev. Med, 2006, 30, 217–224. -PubMed
    1. Xue S, Schlosburg JE and Janda KD, J. Am. Chem. Soc, 2015, 137, 10136–10139. -PMC -PubMed
    1. McDonough M, Aust Prescr, 2015, 38, 106–111. -PMC -PubMed
    1. Janda KD and Treweek JB, Nat. Rev. Immunol, 2011, 12, 67–72. -PubMed

MeSH terms

Substances

LinkOut - more resources